title: Thymosin fraction 5 does not influence urinary tract carcinogenesis by phenacetin and N-butyl-N-(4-hydroxybutyl)nitrosamine in NON/Shi mice.
abstract: The effect of thymosin fraction 5 (TF5) on the promotion and progression phases of urinary tract carcinogenesis induced by consecutive administration of phenacetin and N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) in NON/Shi mice was investigated. The study was carried out twice with a minor modification to the protocol in the second experiment. Fifty-seven male NON/Shi mice in experiment 1 and 100 mice in experiment 2 were each divided into four groups. Phenacetin was administered for 8 weeks in experiment 1 and 12 weeks in experiment 2, and subsequently BBN was given for 6 weeks in both cases, for total observation periods of 30 and 34 weeks, respectively. Sixty micrograms of TF5 per mouse was inoculated subcutaneously twice a week during (group 2) or after (group 3) BBN exposure, or both periods (group 4). Group 1 served as a control group without TF5 treatment. Histopathological examination revealed no effects on either induction of urinary tract carcinomas or distant metastasis from renal pelvic carcinomas in either experiment.
authors.affiliation: First Department of Pathology, Osaka City University, Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Murai
authors.forename: H
authors.initials: H
authors.lastname: Iwata
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: F
authors.initials: F
authors.lastname: Hato
authors.forename: S
authors.initials: S
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: S
authors.initials: S
authors.lastname: Makino
authors.forename: T
authors.initials: T
authors.lastname: Oohara
mesh_terms: D000818:Animals; D002085:Butylhydroxybutylnitrosamine / Q000633:toxicity*; D002273:Carcinogens / Q000633:toxicity*; D003043:Cocarcinogenesis; D003208:Concanavalin A / Q000494:pharmacology; D004347:Drug Interactions; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010615:Phenacetin / Q000633:toxicity*; D010835:Phytohemagglutinins / Q000494:pharmacology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013947:Thymosin / Q000031:analogs & derivatives* / Q000633:toxicity; D014571:Urologic Neoplasms / Q000139:chemically induced*
chemical_list: D002273:Carcinogens; D010835:Phytohemagglutinins; C033782:thymosin fraction 5; D003208:Concanavalin A; D002085:Butylhydroxybutylnitrosamine; D013947:Thymosin; D010615:Phenacetin